| Name | Title | Contact Details |
|---|---|---|
Sandra Estremera-Zink |
Senior Director, Legal and Compliance Operations | Profile |
Christopher Golis |
Director, Legal | Profile |
Gary Francesconi |
Vice President, Legal | Profile |
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical
Duramed Pharmaceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ZO® Skin Health provides a comprehensive range of solutions that will restore skin to a healthy state. From correcting sun damage and pigmentation to acne and aging, ZO® offers a simple, systematic approach to creating and maintaining healthy skin.